Risultati per: Ipotesi sull’origine di Omicron e sua evoluzione

In Reply Drs Hsu and Lai raise some important points regarding our Research Letter that aimed to provide timely results that could inform public health practice, drawing on readily available surveillance data. Our principal finding brought attention to waning vaccine efficacy in children aged 5 to 11 years during the Omicron surge. Since its publication, several other studies have replicated our study’s main conclusions.

New England Journal of Medicine, Ahead of Print.

This retrospective study compares the severity of SARS-CoV-2 infection among persons infected with BA.1 and BA.2 sublineages by vaccination status.

Unsupervised SARS-CoV-2 rapid antigen testing with three commercial kits had 70% to 81% sensitivity during the period when Omicron emerged and became predominant in the Netherlands.

Chi vuole ricevere la quarta dose, anche tra gli under 60, lo potrà fare prenotando la somministrazione all’hub oppure alla farmacia o dal medico di famiglia

Dopo quelli per Omicron 1 al via anche i vaccini per Omicron 4-5, le sottovarianti al momento prevalenti in Italia. In arrivo da lunedì 6 milioni di dosi

Objectives
While almost 60% of the world has received at least one dose of COVID-19 vaccine, the global distribution of vaccination has not been equitable. Only 4% of the population of low-income countries (LICs) has received a full primary vaccine series, compared with over 70% of the population of high-income nations.

Design
We used economic and epidemiological models, parameterised with public data on global vaccination and COVID-19 deaths, to estimate the potential benefits of scaling up vaccination programmes in LICs and lower-middle-income countries (LMICs) in 2022 in the context of global spread of the Omicron variant of SARS-CoV2.

Setting
Low-income and lower-middle-income nations.

Main outcome measures
Outcomes were expressed as number of avertable deaths through vaccination, costs of scale-up and cost per death averted. We conducted sensitivity analyses over a wide range of parameter estimates to account for uncertainty around key inputs.

Findings
Globally, universal vaccination in LIC/LMIC with three doses of an mRNA vaccine would result in an estimated 1.5 million COVID-19 deaths averted with a total estimated cost of US$61 billion and an estimated cost-per-COVID-19 death averted of US$40 800 (sensitivity analysis range: US$7400–US$81 500). Lower estimated infection fatality ratios, higher cost-per-dose and lower vaccine effectiveness or uptake lead to higher cost-per-death averted estimates in the analysis.

Conclusions
Scaling up COVID-19 global vaccination would avert millions of COVID-19 deaths and represents a reasonable investment in the context of the value of a statistical life. Given the magnitude of expected mortality facing LIC/LMIC without vaccination, this effort should be an urgent priority.

Annals of Internal Medicine, Ahead of Print.

A retrospective, observational study in Israel among a population with high rates of prior immunity found nirmatrelvir was associated with improved clinical outcomes in those 65 and older.

Objectives
To investigate changes in beliefs and behaviours following news of the Omicron variant and changes to guidance understanding of Omicron-related guidance, and factors associated with engaging with protective behaviours.

Design
Series of cross-sectional surveys (1 November to 16 December 2021, five waves of data collection).

Setting
Online.

Participants
People living in England, aged 16 years or over (n=1622–1902 per wave).

Primary and secondary outcome measures
Levels of worry and perceived risk, and engagement with key behaviours (out-of-home activities, risky social mixing, wearing a face covering and testing uptake).

Results
Degree of worry and perceived risk of COVID-19 (to oneself and people in the UK) fluctuated over time, increasing slightly around the time of the announcement about Omicron (p

The continued emergence of Omicron variants during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has challenged infection control and posed a risk to individuals with inflammatory bowel disease (IBD) despite vaccination. Previous data suggest an attenuated response to vaccination in adult patients with IBD receiving anti–tumor necrosis factor and other immunomodulatory therapy.1,2 We previously observed a blunted antibody response in children and young adults receiving biologics after SARS-CoV-2 infection.

Objective
To estimate the effectiveness of messenger RNA (mRNA) booster doses during the period of Delta and Omicron variant dominance.

Design
We conducted a matched test-negative case–control study to estimate the vaccine effectiveness (VE) of three and two doses of mRNA vaccines against infection (regardless of symptoms) and against COVID-19-related hospitalisation and death.

Setting
Veterans Health Administration.

Participants
We used electronic health record data from 114 640 veterans who had a SARS-CoV-2 test during November 2021–January 2022. Patients were largely 65 years or older (52%), male (88%) and non-Hispanic white (59%).

Main outcome measures
First positive result for a SARS-CoV-2 PCR or antigen test.

Results
Against infection, booster doses had higher estimated VE (64%, 95% CI 63 to 65) than two-dose vaccination (12%, 95% CI 10 to 15) during the Omicron period. For the Delta period, the VE against infection was 90% (95% CI 88 to 92) among boosted vaccinees, higher than the VE among two-dose vaccinees (54%, 95% CI 50 to 57). Against hospitalisation, booster dose VE was 89% (95% CI 88 to 91) during Omicron and 94% (95% CI 90 to 96) during Delta; two-dose VE was 63% (95% CI 58 to 67) during Omicron and 75% (95% CI 69 to 80) during Delta. Against death, the VE with a booster dose was 94% (95% CI 90 to 96) during Omicron and 96% (95% CI 87 to 99) during Delta.

Conclusions
Among an older, mostly male, population with comorbidities, we found that an mRNA vaccine booster was highly effective against infection, hospitalisation and death. Although the effectiveness of booster vaccination against infection was moderately higher against Delta than against the Omicron SARS-CoV-2 variant, effectiveness against severe disease and death was similarly high against both variants.

La probabilità di sviluppare il Long Covid con Omicron è minore rispetto alla variante Delta: dal 24 al 50% in meno. È quanto emerge da una nuova analisi britannica pubblicata…

È da cinque giorni consecutivi che si registrano più casi rispetti agli stessi giorni della settimana precedente. La sottovariante Ba5 sarebbe già al 13 per cento.

L’immunologo americano Fauci consigliere della Casa Bianca ha già detto di ritenere molto probabile una nuova dose booster per tutti in autunno

A preoccupare le nuove sottovarianti che in Sud Africa sono diventate prevalenti e hanno provocato una quinta ondata e cominciano ad affacciarsi anche in Italia.